Treatment with soluble agonist CTLA-4 Ig fusion protein reduced atherosclerosis progression in hyperlipidemic and hyperhomocysteinemic ApoE−/− mice by competitively inhibiting CD28-CD80/86 co-stimulatory T-cell activation and pro-inflammatory cytokine release [93,94]. This evidence concerns the gene CTLA4 and atherosclerosis.